Innate Pharma SA Class A IPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €2.01
- Day Range
- €2.01–2.05
- 52-Week Range
- €1.86–2.80
- Bid/Ask
- €2.02 / €2.03
- Market Cap
- €163.52 Mil
- Volume/Avg
- 42,910 / 40,756
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 179
- Website
- https://www.innate-pharma.com
Comparables
Valuation
|
Metric
|
IPH
|
NANO
|
ALCLS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.65 | — | 1.41 |
Price/Sales | 6.53 | 5.54 | 11.47 |
Price/Cash Flow | — | — | — |
Price/Earnings
IPH
NANO
ALCLS
Financial Strength
|
Metric
|
IPH
|
NANO
|
ALCLS
|
|---|---|---|---|
Quick Ratio | 2.76 | 1.38 | 1.87 |
Current Ratio | 2.92 | 1.42 | 1.92 |
Interest Coverage | −20.73 | −3.42 | −15.16 |
Quick Ratio
IPH
NANO
ALCLS
Profitability
|
Metric
|
IPH
|
NANO
|
ALCLS
|
|---|---|---|---|
Return on Assets (Normalized) | −17.56% | −41.57% | −34.94% |
Return on Equity (Normalized) | −67.77% | — | −107.90% |
Return on Invested Capital (Normalized) | −39.20% | −103.38% | −57.16% |
Return on Assets
IPH
NANO
ALCLS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jfcvdhbd | Prvx | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mwnflnpv | Glcwmf | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xzqgtnkzb | Hpvlj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lxgdlsmd | Mwkwc | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Gnqlwfhz | Mbfm | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Qhnbrnhlt | Gydh | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ywcwzrf | Bhm | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Svcbzpzcp | Fxcfz | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nmtzwkrjr | Jffkgm | $13.4 Bil | |||
| Incyte Corp
INCY
| Prkwdnxyz | Bbhpztm | $12.7 Bil |
United States